/PRNewswire/ Based on hhc (human health care) concept, our corporate philosophy, Eisai is committed to improve patients health outcomes and quality of life,.
The study found that baseline tau PET (Positron emission tomography) is the strongest independent predictor of cognitive decline.Sweden: In patients with Alzheimer s disease having a mild cognitive.
The Alzheimer s disease community has become accustomed to false hope, disappointment,
and controversy. With an estimated 55 million people worldwide affected by dementia,
the need for an effective treatment is undeniable. But efforts to develop a drug that
can modify the course of Alzheimer s disease, by using antibodies to clear amyloid-beta
(Aβ) from the brain, have endured numerous setbacks over the past 20 years. Almost
a decade ago, the first anti-Aβ antibodies tested in phase 3 trials, bapineuzumab
and solanezumab, did not improve clinical outcomes in mild to moderate Alzheimer s
disease.
AXS-05 statistically significantly delayed time to relapse of Alzheimer’s disease agitation versus placebo AXS-05 statistically significantly prevented relapse of Alzheimer’s disease. | November 28, 2022